Matinas BioPharma Holdings (MTNB) Depreciation & Amortization (CF) (2013 - 2025)
Matinas BioPharma Holdings (MTNB) reported Depreciation & Amortization (CF) of $3000.0 for Q4 2025, down 96.67% year-over-year from $90000.0 in Q4 2024, and up 400.0% quarter-over-quarter from -$1000.0 in Q3 2025.
Matinas BioPharma Holdings (MTNB) Depreciation & Amortization (CF) (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $3000.0 in Q4 2025.
- Depreciation & Amortization (CF) for Q4 2025 came in at $3000.0, down 96.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $14000.0 (down 95.16% YoY), and the FY2025 annual result was $32000.0, down 91.23% from the prior year.
- Depreciation & Amortization (CF) climbed to $3000.0 in Q4 2025 per MTNB's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $98000.0 in Q3 2023 and troughed at -$1000.0 in Q3 2025.
- A 5-year average of $68150.0 and a median of $87500.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 46.87% in 2022, then slumped 101.1% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $64579.0 in 2021, then surged by 44.01% to $93000.0 in 2022, then increased by 4.3% to $97000.0 in 2023, then slipped by 7.22% to $90000.0 in 2024, then sank by 96.67% to $3000.0 in 2025.
- Business Quant data shows MTNB's Depreciation & Amortization (CF) at $3000.0 in Q4 2025, -$1000.0 in Q3 2025, and $12000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Dec 31, 2023 | 97,000.00 |
| Dec 31, 2023 | 97,000.00 |
| Sep 30, 2023 | 98,000.00 |
| Sep 30, 2023 | 98,000.00 |